Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $5.9 million.

  • Biofrontera's Cash & Equivalents rose 17.83% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 17.83%. This contributed to the annual value of $5.9 million for FY2024, which is 339.69% up from last year.
  • Latest data reveals that Biofrontera reported Cash & Equivalents of $5.9 million as of FY2024, which was up 339.69% from $1.3 million recorded in FY2023.
  • Biofrontera's 5-year Cash & Equivalents high stood at $24.5 million for FY2021, and its period low was $1.3 million during FY2023.
  • In the last 3 years, Biofrontera's Cash & Equivalents had a median value of $5.9 million in 2024 and averaged $8.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 92.20% in 2023, then soared by 339.69% in 2024.
  • Over the past 5 years, Biofrontera's Cash & Equivalents (Yearly) stood at $8.1 million in 2020, then spiked by 203.02% to $24.5 million in 2021, then dropped by 29.89% to $17.2 million in 2022, then crashed by 92.20% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024.